{"id":"NCT00478205","sponsor":"Eisai Inc.","briefTitle":"Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease","officialTitle":"Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2009-06","completion":null,"firstPosted":"2007-05-24","resultsPosted":"2013-02-05","lastUpdate":"2014-07-11"},"enrollment":1467,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"Aricept (donepezil SR 23 mg)","otherNames":["Donepezil hydrochloride"]},{"type":"DRUG","name":"Aricept (donepezil IR 10 mg)","otherNames":["Donepezil hydrochloride"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.","primaryOutcome":{"measure":"Change From Baseline to Week 24 in SIB Total Score","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Donepezil SR 23 mg","deltaMin":2.6,"sd":0.58},{"arm":"Donepezil IR 10 mg","deltaMin":0.4,"sd":0.66}],"pValues":[]},"eligibility":{"minAge":"45 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["24073978","22930699","22572767","21689411","21612646","20678673"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":963},"commonTop":["Nausea","Diarrhoea","Vomiting","Anorexia"]}}